PHARMEXCIL engaged senior Commerce and Pharma Ministry officials to align policy, boost MSME participation, and sustain India ...

Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for ...

Fitch believes companies with portfolios focused on oncology, immunology, rare diseases, vaccines and metabolic or ...

India’s pharmaceutical exports reached US$ 30.47 billion in FY 2024–25, and the sector remains optimistic about further growth, driven by strong global demand and resilient production capabilities.

Sun Pharma's Managing Director, Kirti Ganorkar, predicts that new age medicines for obesity and diabetes will drive the ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

India’s pharmaceutical exports reached $30.47 billion in FY 2024–25, registering a 9.4 per cent year-on-year growth, and are ...

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

In FY25, India's pharmaceutical exports reached a record high, surpassing $30 billion (approximately $30.47 billion), a ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Sun Pharma highlights obesity treatment drugs as a growth driver for India's pharma industry, enhancing access to GLP-1 ...